![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
7MB |
![[thumbnail of Supplementary Data]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Data)
3MB |
| Item Type: | Article |
|---|---|
| Title: | Outcomes of CAR-T cell therapy and bispecific antibodies as single-modality and sequential strategies in relapsed/refractory multiple myeloma |
| Creators: |
Merz, Maximilian, Jelinek, Tomas, Pabst, Thomas, Teipel, Raphael, Albici, Anca-Maria, von Tresckow, Bastian, Teichert, Marcel, Demel, Uta Margareta  ORCID: https://orcid.org/0000-0002-6480-4185, Busse, Antonia ORCID: https://orcid.org/0000-0002-3470-6947, Wesener, Marie Christine, Holderried, Tobias A.W., Schmitz, Friederike, Rößiger, Friedrich-Linus, Müller, Fabian, Hoffmann, Michele, Stölzel, Friedrich, Tovar, Natalia, Baermann, Ben-Niklas, Stork, Martin, Jungova, Alexandra, Minarik, Jiri, Radocha, Jakub, Spicka, Ivan, Pour, Ludek, Novak, Polona, Slajpah, Klara, Rener, Karla, Keller, Ulrich ORCID: https://orcid.org/0000-0002-8485-1958, Bohl, Stephan, Fandrei, David, Born, Patrick, Vucinic, Vladan, Kröger, Nicolaus, Strassl, Irene, Schub, Natalie, Hájek, Roman, Sever, Matjaz, Fernández de Larrea, Carlos and Gagelmann, Nico
|
| Abstract: | We explored single or consecutive chimeric antigen receptor (CAR) T and bispecific antibody (BsAb) treatment modalities as correlates of clinical outcomes, by complementary bias-correction analysis of a retrospective multicenter study of 640 patients with relapsed/refractory multiple myeloma. The sequential use of both modalities seemed to yield the most favorable survival trajectories. Initiating treatment with CAR T [idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel), cesnicabtagene autoleucel (cesni-cel)] was associated with longer remission. However, mortality from early progression was similar regardless of initial modality, suggesting that resistance may negate initial efficacy difference. On the product level, the benefit of CAR T seemed to be driven by cilta-cel and cesni-cel, whereas BsAbs showed at least comparable outcomes with ide-cel. These exploratory findings highlight the critical importance of treatment sequencing in optimizing long-term outcomes and underscore the need for equitable and timely access to both modalities across healthcare systems. |
| Keywords: | Multiple Myeloma, Chimeric Antigen Receptor T Cells, Bispecific Antibodies, Ciltacabtagene Autoleucel, Idecabtagene Vicleucel, Cesnicabtagene Autoleucel, Teclistamab, Talquetamab, Elranatamab |
| Source: | Blood Cancer Discovery |
| ISSN: | 2643-3230 |
| Publisher: | American Association for Cancer Research |
| Volume: | 7 |
| Number: | 5 |
| Page Range: | 697-710 |
| Date: | 3 September 2026 |
| Official Publication: | https://doi.org/10.1158/2643-3230.bcd-25-0461 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
